13F Holdings
中文EN

INCY INCYTE CORP

Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 879169 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY24.9%
TTM net income YoY-66.1%
TTM EPS YoY-66.8%
Revenue 3-yr CAGR18.5%
Net income 3-yr CAGR-1.7%

Margins

Gross margin92.7%
Operating margin10.4%
Net margin6.7%
FCF margin—
EBITDA margin12.1%

Returns

ROE7.8%
ROA5.9%
ROIC (approx.)13.9%
Asset turnover0.88x

Leverage & solvency

Liabilities / assets22.6%
Debt / equity0.00x
Current ratio3.84x
Interest coverage267.97x

Cash quality & payout

Operating cash flow / net income1.85x
Accruals ratio-5.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$5.14B$4.24B$3.70B$3.39B$2.99B
Cost of revenue$372.13M$312.07M$254.99M$207.00M$150.99M
Gross profit$4.77B$3.93B$3.44B$3.19B$2.84B
R&D expense$2.05B$2.61B$1.63B$1.59B$1.46B
SG&A expense$1.38B$1.24B$1.16B$1.00B$739.56M
Operating income$1.51B$61.37M$620.52M$579.44M$585.78M
Interest expense$2.43M$2.28M$2.55M$2.67M$1.91M
Pretax income$1.66B$316.63M$834.22M$529.12M$570.44M
Income tax$377.80M$284.01M$236.62M$188.46M-$378.14M
Net income$1.29B$32.62M$597.60M$340.66M$948.58M
EBITDA$1.61B$150.61M$703.18M$647.29M$643.62M
EPS (basic)6.590.162.671.534.30
EPS (diluted)6.410.152.651.524.27
Weighted avg. shares (diluted)200.70M210.53M225.93M223.96M222.07M
Balance sheet
Cash & equivalents$3.10B$1.69B$3.22B$2.95B$2.06B
Short-term investments——$442.67M$287.54M$290.75M
Inventory$101.06M$58.87M$62.97M$41.99M$27.90M
Current assets$5.02B$3.24B$4.65B$4.09B$3.12B
PP&E, net$730.88M$763.41M$751.51M$739.31M$723.92M
Goodwill$133.00M$155.59M$155.59M$155.59M$155.59M
Total assets$6.96B$5.44B$6.78B$5.84B$4.93B
Current liabilities$1.52B$1.64B$1.24B$1.16B$854.31M
Total liabilities$1.79B$2.00B$1.59B$1.47B$1.16B
Shareholders' equity$5.17B$3.45B$5.19B$4.37B$3.77B
Shares outstanding198.46M193.43M224.29M222.75M221.08M
Cash flow statement
Operating cash flow$1.41B$335.34M$496.49M$969.94M$749.49M
Capital expenditure———$77.83M$181.01M
Free cash flow———$892.11M$568.48M
Investing cash flow-$102.61M$157.52M-$207.68M-$78.54M-$207.70M
Financing cash flow$101.04M-$2.02B-$20.03M-$794,000$6.18M
Depreciation & amortization$93.29M$89.25M$82.66M$67.86M$57.84M
Stock-based compensation$249.35M$266.06M$215.89M$188.42M$183.01M
Share buybacks$0$2.00B$0$0—

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.